ライフサイエンスコーパス: traveler

1 orporates inflows and outflows of interstate travelers.

2 n imported into many nonendemic countries by travelers.

3 a remains a common problem for international travelers.

4 ay not be representative of all ill returned travelers.

5 ber of cases distributed across the globe by travelers.

6 se cities had already received many infected travelers.

7 through international travel by unvaccinated travelers.

8 ing identifiable cause of fever in returning travelers.

9 focus posttravel evaluation of ill returned travelers.

10 tract hundreds of thousands of international travelers.

11 ffer consistent pretravel preventive care to travelers.

12 -identified pretravel data for international travelers.

13 ics that collect data from ill international travelers.

14 o cause life-threatening illness in returned travelers.

15 amplification (LAMP) kit in febrile returned travelers.

16 C metro area to include leisure and business travelers.

17 for advice before travel or by ill returned travelers.

18 effectively boosted immunity in JE-MB-primed travelers.

19 f the overall population of US international travelers.

20 rditis in regions where it is endemic and in travelers.

21 mptoms associated with NoV diarrhea in these travelers.

22 ncoming Brazilian travelers and returning US travelers.

23 e risk was observed among incoming Brazilian travelers.

24 ess of this schedule for chemoprophylaxis in travelers.

25 quired measles cases, costing $14.8M per 10M travelers.

26 nsuitable for children and primarily used by travelers.

27 ontributing factor to the risk of malaria in travelers.

28 and 35 US-acquired cases at $190.3M per 10M travelers.

29 d and popular destinations for international travelers.

30 rate, and was well tolerated and accepted by travelers.

31 e than their proportion in incoming infected travelers.

32 nd are mostly due to infections in returning travelers.

33 relatively rare cause of malaria in returned travelers.

34 n imported into many nonendemic countries by travelers.

35 P. malariae diagnosis and clinical course in travelers.

36 ut data did not support direct links between travelers.

37 of semen testing for Zika virus from 2 male travelers.

38 disorders, shift workers, and transmeridian travelers.

39 Three travelers (0.5%) acquired carbapenemase-producing Entero

40 rabies immunoglobulin (HRIG) to only 7 of 50 travelers (14%) who sought care abroad and for whom HRIG

41 Only 58 travelers (5%) had received typhoid vaccine.

42 elers [65%]) or at nonacademic centers (1777 travelers [51%]).

43 Among 824 participating travelers, 574 provided fecal samples before and after t

44 refusal was most frequent in the South (1432 travelers [63%]) and in nonacademic centers (1178 travel

45 vaccinated were evaluated in the South (2262 travelers [65%]) or at nonacademic centers (1777 travele

46 lers [63%]) and in nonacademic centers (1178 travelers [66%]).

47 Twenty-four travelers (8%) required medical attention because of ill

48 ere recorded prospectively among 430 Finnish travelers, 90 (21%) of whom acquired ESBL-PE abroad.

49 sible differential diagnoses of ill returned travelers according to destination and reason for travel

50 t travelers save money for longer trips when travelers adhere to malaria recommendations and prophyla

51 associated costs and benefits resulting from traveler adherence to malaria chemoprophylaxis were calc

52 y-confirmed ESBL-PE infections among the 430 travelers, all in subjects who screened ESBL-PE negative

53 Structured questionnaire completed by traveler and provider during pretravel consultation.

54 We measured pitting in 83 French travelers and 42 Malian children treated for malaria wit

55 Isolates from all travelers and a Bayelsa case shared a most recent common

56 n many parts of the world, that is spread by travelers and adapts to new mosquito vectors that live i

57 ading diarrheagenic bacterial pathogen among travelers and children in resource-limited regions.

58 t other key enteric pathogens can be used by travelers and clinicians in pre- and posttravel consulta

59 is a global health problem and of concern to travelers and deploying military personnel with developm

60 can assist clinicians to advise prospective travelers and guide pretravel preparation, including iti

61 osinophilia is a common finding in returning travelers and immigrants from parasite-endemic areas.

62 articularly useful in military personnel and travelers and in the control of outbreaks.

63 anagement of malaria of different species in travelers and migrants in nonendemic areas.

64 ellents are important prophylactic tools for travelers and populations living in endemic areas of mal

65 lity of Toscana virus infection in returning travelers and provides information on how to obtain test

66 om Brazil, including both incoming Brazilian travelers and returning US travelers.

67 d lead to therapeutic options for both space travelers and terrestrial patients.

68 Escherichia coli (ETEC) is a common cause of travelers' and postweaning diarrhea in humans and swine,

69 ay not be representative of all ill returned travelers, and denominator data are unavailable.

70 or cause of infectious diarrhea in children, travelers, and deployed military personnel.

71 one metabolism remain key concerns for space travelers, and ground-based models of space flight have

72 s; the percentage of previously-unvaccinated travelers; and the percentage of travelers returning to

73 Travelers are at risk of acquiring MRE in these regions,

74 Space travelers are exposed to unique forms of ionizing radiat

75 la Paratyphi A is an emerging infection, and travelers are increasingly at risk.

76 Travelers are more likely to be sociodemographically adv

77 cannot estimate disease risk because healthy travelers are not included in the denominator.

78 ihood of measles exposure, especially if the travelers are previously unvaccinated or will return to

79 Travelers are sentinels for global Zika virus circulatio

80 e odds of malaria infection among off-island travelers are significantly higher than the rest of the

81 Clinicians encountering ill travelers arriving from countries with widespread Ebola

82 y currently drive clinical evaluation of ill travelers arriving from Sierra Leone, Liberia, and Guine

83 antifies the risk of YF virus (YFV) infected travelers arriving in the United States via air travel f

84 ta collected by wearables from more than 100 travelers as they cross time zones using a smartphone ap

85 e associations were observed among nonimmune travelers as well as immigrants from endemic areas.

86 From February 2012 to April 2013, travelers attending 6 international vaccination centers

87 consultations saved healthcare payers a per-traveler average of $14 (9-day trip) to $372 (30-day tri

88 Twenty-one percent (90/430) of the travelers became colonized by ESBL-PE and none by CPE.

89 e Ivory Coast had the highest proportions of travelers being infected at 8 and 7 per 1000, respective

90 proven P. malariae monoinfections in Israeli travelers between January 2008 and January 2017 were ret

91 iated with malaria prevention provided to US travelers bound for West Africa.

92 Vivax malaria causes significant illness in travelers, but current first-line chemoprophylaxis agent

93 been described in hyperparasitemic nonimmune travelers, but it is unknown if African children are equ

94 Vivax malaria causes significant illness in travelers, but relapses of vivax malaria are not prevent

95 Three months after return, 4.7% of the travelers carried MRE.

96 ance of NoV infection in three international traveler cohorts with diarrhea acquired in three develop

97 For travelers, consultations resulted in a range of net cost

98 ndent risk factors, with up to 80% of TD+AB+ travelers contracting ESBL-PE.

99 er skin infections and nasal colonization in travelers contribute to the global spread of such strain

100 prove MMR vaccination among US international travelers could reduce measles cases, but are costly.

101 rubella (MMR) vaccination among departing US travelers could reduce the clinical impact and costs of

102 se in MMR vaccination of eligible U.S. adult travelers could reduce the likelihood of importation and

103 ons of Enterobacteriaceae infection included travelers' diarrhea (TD) (75/90 subjects) and urinary tr

104 Geographic region, occurrence of travelers' diarrhea (TD), age, and use of antimicrobial

105 appears promising as a chemoprophylaxis for travelers' diarrhea and as a treatment of portal systemi

106 Rifaximin is effective for the treatment of travelers' diarrhea and can be considered as the treatme

107 uals susceptible to Escherichia coli-induced travelers' diarrhea and in tear fluid derived from viral

108 NoVs were identified in 10.2% of cases of travelers' diarrhea and, overall, was the second most co

109 ed in the United States for the treatment of travelers' diarrhea caused by noninvasive diarrheagenic

110 Large field studies of travelers' diarrhea for multiple destinations are limite

111 NoVs are important pathogens of travelers' diarrhea in multiple regions of the world.

112 Recommended treatment for travelers' diarrhea includes the combination of an antib

113 When invasive travelers' diarrhea pathogens are suspected, an alternat

114 i (ETEC) is a leading cause of childhood and travelers' diarrhea, for which an effective vaccine is n

115 is responsible for causing severe infant and travelers' diarrhea, gastroenteritis and hemolytic uremi

116 onducted for the treatment and prevention of travelers' diarrhea, the treatment of portal systemic en

117 received an antibiotic for self-treatment of travelers' diarrhea.

118 as the treatment of choice for uncomplicated travelers' diarrhea.

119 cognized as an important cause of infant and travelers' diarrhoea, exhibits an aggregative, stacked-b

120 nations and itineraries of Global TravEpiNet travelers differed from those of the overall population

121 ns and epidemiology of Zika virus disease in travelers exposed in the Americas.

122 ns and epidemiology of Zika virus disease in travelers exposed in the Americas.

123 f the least invasive methods to assess urban traveler exposure.

124 Through 2 international traveler-focused surveillance networks (GeoSentinel and

125 ed patients represent an increasing group of travelers, for business, tourism, and visiting friends a

126 Travelers from all regions except Southeast Asia present

127 Febrile travelers from countries with unique endemic pathogens p

128 to occur and caused infection and deaths in travelers from non-endemic regions.

129 For travelers from nonendemic countries, Vero cell-derived v

130 burden of shigellosis is either in returning travelers from shigellosis-endemic regions or in men who

131 ncluded age (0 to 5 and 11 to 15 years), and travelers from Siaya County, located to the north of Ngo

132 the recognition of Ebola virus disease among travelers from West Africa, cases of Middle East respira

133 veillance of human movement patterns and key traveler groups, it is hoped that interventions can be i

134 e of NoVs as a cause of diarrhea acquired by travelers in developing countries is not well known.

135 athogen that causes diarrhea in children and travelers in developing countries.

136 d measles should target all vaccine-eligible travelers, including catch-up vaccination of susceptible

137 was not cost effective for all international travelers (incremental cost-effectiveness ratio [ICER] $

138 Orlando-had the highest risk of receiving a traveler infected with YFV.

139 adverse outcomes of Zika virus disease among travelers infected in the Americas and show a need for g

140 adverse outcomes of Zika virus disease among travelers infected in the Americas and show a need for g

141 on affected millions of people, and infected travelers introduced CHIKV to new regions.

142 Whether the effects are similar in air travelers is unknown.

143 avel health consultations help international travelers manage travel-related illness risks through ed

144 sure to ultraviolet B light, including space travelers, may not receive enough vitamin D.

145 To navigate efficiently, a traveler must establish a heading using a frame of refer

146 ond most common diagnosis among nonimmigrant travelers (n = 95 [12.3%]).

147 In travelers, O-iRBCs peaked at 107.7% initial parasitemia.

148 tious HIV-1 in semen becomes an adventitious traveler on the pathway leading to normal human reproduc

149 the profiles of the photographers to derive travelers' origins.

150 to be men (73% vs. 54% of low-infection risk travelers, P=0.018) or born outside the United Stated or

151 and pretravel healthcare of US international travelers, particularly those at higher risk of travel-a

152 Travelers planning to attend mass events will encounter

153 ions can be implemented to protect and treat travelers, prevent onward transmission in low transmissi

154 In travelers primed with JE-MB, vaccination response rates

155 cNuclei predicts subnuclear compartments and traveler proteins accurately.

156 that are also native to other compartments (traveler proteins).

157 monly prescribed antimalarial drug, and most travelers received an antibiotic for self-treatment of t

158 Nonvaccination due to traveler refusal was most frequent in the South (1432 tr

159 e, 1689 (48%) were not vaccinated because of traveler refusal, 966 (28%) because of provider decision

160 series of JE-VC has been recommended to all travelers regardless of previous vaccination history.

161 Fifty-nine percent of travelers reported >/=1 medical condition.

162 Only 40.5% of all ill travelers reported pretravel medical visits.

163 Ninety-six percent of travelers reported that they did not seek specific pretr

164 Prevention of malaria in travelers requires detailed knowledge of malaria epidemi

165 relation to ocular changes reported in space travelers requires further prospective studies.

166 ness occurred in only 26, 9, and 7 returning travelers, respectively.

167 oV into the Republic of Korea by an infected traveler resulted in a hospital outbreak of MERS that en

168 es outside of ZIKV-endemic areas as infected travelers return to their home countries.

169 Ten Belgian travelers returned from Mali with a Schistosoma haematob

170 ctious to humans by describing the case of a traveler returning from the Central African Republic inf

171 portations and the subsequent spread from US travelers returning from abroad are responsible for most

172 Carriage lasted longer in travelers returning from Asia and in travelers with a hi

173 Knowledge of illness in travelers returning from Brazil can assist clinicians to

174 only a few cases have been reported in U.S. travelers returning from Europe, most cases are likely u

175 ost travel-associated infections occurred in travelers returning from Latin America and the Caribbean

176 1 October 2009-30 November 2009, 37 Israeli travelers returning from Nepal were diagnosed with S. Pa

177 . Paratyphi A infection was noted in Israeli travelers returning from Nepal.

178 rickettsiosis, occurring in as many as 5% of travelers returning from rural subequatorial Africa.

179 Among travelers returning from sub-Saharan Africa, rickettsial

180 We find that travelers returning from the United States of America si

181 ca and compare it to parasites isolated from travelers returning from these regions of Africa, as wel

182 ause of illness in West Africa and among the travelers returning from this region with an acute febri

183 positive samples were collected from Israeli travelers returning from Zika-endemic areas.

184 Clinicians evaluating travelers returning ill from Malaysia with myalgia, with

185 nvaccinated travelers; and the percentage of travelers returning to US communities with heterogeneous

186 cs that compute probabilities reminiscent of traveler's and divergent ratios.

187 ater, food and environmental samples as well traveler's baggage is a great challenge of the time for

188 encoding OPG (TNFRSF11B) are associated with traveler's diarrhea (TD) among North American travelers

189 herichia coli (ETEC) is the leading cause of traveler's diarrhea and children's diarrhea worldwide.

190 Prevention of traveler's diarrhea by dietary avoidance measures is oft

191 Acquiring traveler's diarrhea causes 12% to 46% of travelers to ch

192 is the standard treatment in self-therapy of traveler's diarrhea except when patients are in South or

193 Improved hygiene has reduced the risk of traveler's diarrhea from 20% or more (for a 2-week stay)

194 ugh improved hygiene has reduced the risk of traveler's diarrhea in many destinations, the risk remai

195 scherichia coli (ETEC) is a leading cause of traveler's diarrhea worldwide.

196 man diseases, including cholera, diphtheria, traveler's diarrhea, and whooping cough.

197 acterial enterotoxins, including cholera and traveler's diarrhea, remain a major global health proble

198 olated from the stools of Danish adults with traveler's diarrhea.

199 with community-acquired gastroenteritis and traveler's diarrhea.

200 012-April 2014 was performed for articles on traveler's diarrhea.

201 occur in 3% to 17% of patients who have had traveler's diarrhea.

202 that is used in Europe as a preventative of traveler's diarrhea.

203 terial cause of diarrheal disease, including traveler's diarrhea.

204 hat the cooperative behavior observed in the Traveler's Dilemma can be explained in an evolutionary f

205 an quantitatively reproduce data that from a Traveler's Dilemma experiment.

206 der behavior in one such social dilemma, the Traveler's Dilemma, that has received considerable atten

207 ired settings, as well as from patients with traveler's or persistent diarrhea.

208 perspectives: the healthcare payer's and the traveler's.

209 y for short- and longer-term trips, and that travelers save money for longer trips when travelers adh

210 Returning travelers seeking medical care have a diagnosis of gastr

211 sles immunity status of departing U.S. adult travelers seeking pretravel consultation and to assess r

212 Malaria remains a common diagnosis among travelers seen at GeoSentinel sites.

213 ed in sequential blood samples from returned travelers sent for pathogen testing to a specialist para

214 seling for those visiting high-risk regions, travelers should be advised against taking antibiotics f

215 Geographic variation in the risk of SSTIs in travelers supports a globally heterogeneous distribution

216 In returning travelers, the clinical assessment can provide substanti

217 In vaccine-naive travelers, the vaccination response rate for test strain

218 ective live vaccine (17D) is widely used for travelers to and residents of areas in which yellow feve

219 Travelers to Brazil will encounter locally endemic infec

220 imarily identified infectious diseases among travelers to Brazil.

221 ing traveler's diarrhea causes 12% to 46% of travelers to change their travel plans.

222 h generally SOTR were able to travel safely, travelers to destinations at high-risk for infection had

223 ia in pregnant women who are residents of or travelers to epidemic or endemic regions is needed to av

224 he geographic region, with 17 of 100 (17.0%) travelers to Guatemala, 23 of 194 (11.9%) travelers to I

225 ng hemodialysis patients), or HIV infection; travelers to HBV-endemic regions; and adults seeking pro

226 se of illness; illness was more likely among travelers to high-infection risk (18%) than low-risk (6%

227 accine that can rapidly protect short-notice travelers to high-risk areas and help control explosive

228 es case averted) or was even cost saving for travelers to hot spots, especially if travelers were pre

229 %) travelers to Guatemala, 23 of 194 (11.9%) travelers to India, and 3 of 79 (3.8%) travelers to Mexi

230 Approximately 40% of US travelers to less developed countries experience diarrhe

231 rhea is the most common illness that affects travelers to low-income regions of the world.

232 Significant numbers of travelers to malarious countries still take no chemoprop

233 1.9%) travelers to India, and 3 of 79 (3.8%) travelers to Mexico testing positive for NoVs from 2002

234 raveler's diarrhea (TD) among North American travelers to Mexico.

235 "-like outbreak was identified among Israeli travelers to Nepal.

236 of concern due to the potential for infected travelers to spread the virus to countries where vectors

237 Approximately 8 percent of travelers to the developing world require medical care d

238 undifferentiated febrile illness (UFI) among travelers to the developing world, and these pathogens a

239 One-third of the 100 million travelers to the tropics annually acquire extended-spect

240 rhea in children of developing countries and travelers to these countries, is to protect against heat

241 ions at higher risk for infectious diseases; travelers to these destinations were more likely to be m

242 n or expatriates of developing countries and travelers to these regions where follow-up studies have

243 ea in infants in developing countries and in travelers to those regions.

244 ildren living in developing countries and in travelers to those regions.

245 The exact source of infection among travelers to Tioman Island remains unclear but needs to

246 MRE acquisition is very frequent among travelers to tropical regions.

247 Malaria commonly infects residents of and travelers to tropical regions.

248 Providers must counsel travelers to yellow fever (YF)-endemic areas, although r

249 We analyzed hematologic parameters in 123 travelers treated with AS for severe malaria.

250 We quantified pitting in 81 travelers treated with oral antimalarial therapy.

251 s where the disease burden is low (so-called travelers vaccines), they have demonstrated a lower prot

252 More than 300 million travelers visit regions with poor hygiene annually.

253 avel destination and reason for travel, with travelers visiting friends and relatives in their countr

254 the overall pooled relative risk for VTE in travelers was 2.0 (95% CI, 1.5 to 2.7).

255 xcluded, the pooled relative risk for VTE in travelers was 2.8 (CI, 2.2 to 3.7), without significant

256 The presence of PVL in S. aureus in travelers was associated with complicated disease, reduc

257 a and in the predominant genogroup infecting travelers was demonstrated, dependent upon the specific

258 on specific diagnosis among 770 nonimmigrant travelers was malaria (n = 310 [40.3%]), with Plasmodium

259 Compared with matched control patients, travelers were 74% more likely to be transplanted (aHR [

260 The pathogens identified most commonly in travelers were Campylobacter (42%), nontyphoidal Salmone

261 One hundred twenty travelers were divided into 4 groups: Volunteers with no

262 Inactivated vaccines given to European travelers were found to elicit protective levels of neut

263 40 810 adult travelers were included; providers considered 6612 (16%)

264 ng for travelers to hot spots, especially if travelers were previously unvaccinated or returning to U

265 We assumed that US travelers were subject to the same daily risk of YF infe

266 95% of currently vaccine-eligible pediatric travelers were unvaccinated, and antimicrobial-resistant

267 ndiarrheagenic E. coli isolates from healthy travelers were used as controls.

268 r's assessment, but fewer than half of these travelers were vaccinated.

269 The majority of Global TravEpiNet travelers were visiting low- or lower-middle-income coun

270 Seventy-five percent of travelers were visiting malaria-endemic countries, and 3

271 stance to common antimicrobials in returning travelers, where severe disease requires empirical treat

272 We report a traveler who acquired a Salmonella enterica subspecies e

273 and pretravel healthcare of US international travelers who are at increased risk of travel-associated

274 Chemoprophylaxis should be restricted to travelers who are at risk of severe complications of dia

275 through mathematical modeling entirely, but travelers who better followed the optimal schedules repo

276 We describe 1586 ill returned travelers who had visited Brazil and were seen at a GeoS

277 Of U.S. adult travelers who presented for pretravel consultation at GT

278 Clinicians evaluating high-altitude travelers who report moderate to severe limitations in a

279 retravel healthcare from 13235 international travelers who sought pretravel consultation at these sit

280 OPG+1181G>C) was associated with TD in white travelers who stayed in Mexico for >1 week during the su

281 ts were (1) late initiation of rabies PEP in travelers who waited to seek medical care until returnin

282 Most MMR-eligible travelers who were not vaccinated were evaluated in the

283 ections are imported from endemic regions by travelers, who can become new sources of mosquito infect

284 Patients: Ill returned travelers with a confirmed, probable, or clinically susp

285 Ill returned travelers with a confirmed, probable, or clinically susp

286 The best value is for travelers with a high likelihood of measles exposure, es

287 nger in travelers returning from Asia and in travelers with a high relative abundance of MRE at retur

288 these examinations is limited, especially in travelers with a low worm burden.

289 es fragilis (ETBF), in 201 U.S. and European travelers with acute diarrhea acquired in Mexico, Guatem

290 solates (as defined by HEp-2 adherence) from travelers with diarrhea and in 18 EAEC isolates from tra

291 Stool samples from 571 international travelers with diarrhea were evaluated for traditional e

292 Among the 28 ill returned travelers with human immunodeficiency virus (HIV) infect

293 SNPs in the OPG gene for 968 North American travelers with or without TD.

294 Methods and Twenty-six returning travelers with schistosomiasis (based on positive result

295 uent in the lesional and nasal isolates from travelers with SSTIs but could not be found in the nares

296 Stool samples from travelers with TD were evaluated for the presence of ent

297 cal, and exposure-related characteristics of travelers with those of nontravelers and estimate the ri

298 Measles remains a risk for travelers, with 94 measles diagnoses reported to the Geo

299 s with diarrhea and in 18 EAEC isolates from travelers without diarrhea.

300 Common causes of chronic diarrhea among travelers worldwide include protozoan parasites.